MeSH term
Frequency | Condition_Probility | Humans | 45 | 0.0 |
Amino Acid Sequence | 12 | 0.0 |
Animals | 18 | 0.0 |
Binding Sites | 3 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Hela Cells | 5 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Kinetics | 3 | 0.0 |
Mice | 8 | 0.0 |
Models, Chemical | 2 | 0.0 |
Molecular Sequence Data | 11 | 0.0 |
Oxidation-Reduction | 7 | 0.0 |
Peroxidases/*chemistry/*physiology | 2 | 100.0 |
Rats | 7 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 30 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Thioredoxin/chemistry | 2 | 66.0 |
Time Factors | 4 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Peroxidases/chemistry/*metabolism | 2 | 66.0 |
Phosphorylation | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Adult | 11 | 0.0 |
Aged | 8 | 0.0 |
Brain Injuries/*diagnosis/physiopathology | 2 | 100.0 |
*Cerebrovascular Circulation | 2 | 5.0 |
Female | 14 | 0.0 |
Male | 12 | 0.0 |
Middle Aged | 12 | 0.0 |
Blotting, Western | 7 | 0.0 |
Catalysis | 3 | 0.0 |
Catalytic Domain | 2 | 0.0 |
Cysteine/chemistry | 2 | 1.0 |
Mutation | 5 | 0.0 |
*Oxidoreductases | 2 | 2.0 |
Peroxidases/genetics/*metabolism | 3 | 50.0 |
Protein Binding | 3 | 0.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Oxidative Stress | 2 | 0.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 1.0 |
Antioxidants/metabolism | 4 | 4.0 |
Cell Line | 7 | 0.0 |
Reactive Oxygen Species/metabolism | 5 | 1.0 |
Transfection | 2 | 0.0 |
Antioxidants/*metabolism | 2 | 2.0 |
Gene Expression | 3 | 0.0 |
Hydrogen Peroxide/pharmacology | 3 | 1.0 |
Immunoblotting | 3 | 0.0 |
Peroxidases/*metabolism | 5 | 17.0 |
Aged, 80 and over | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Culture Techniques | 2 | 0.0 |
Peroxidases/*genetics | 2 | 18.0 |
Pregnancy | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 3 | 0.0 |
Signal Transduction | 3 | 0.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Immunohistochemistry | 10 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Enzyme Activation | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Comparative Study | 4 | 0.0 |
Drug Interactions | 2 | 0.0 |
Blotting, Northern | 3 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
DNA, Complementary/chemistry/genetics | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
*Neoplasm Proteins | 3 | 0.0 |
Carcinoma, Non-Small-Cell Lung/*enzymology/*physiopathology | 2 | 100.0 |
Carcinoma, Small Cell/*enzymology/*physiopathology | 2 | 100.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Disease Progression | 3 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Lung Neoplasms/*enzymology/*physiopathology | 2 | 100.0 |
Peroxidases/*biosynthesis | 5 | 71.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Cysteine/genetics | 2 | 1.0 |
Hydrogen Peroxide/metabolism | 5 | 4.0 |
Proteins/metabolism | 2 | 0.0 |
Thioredoxin/metabolism | 2 | 18.0 |
COS Cells | 2 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Peroxidases/*analysis | 2 | 18.0 |
Cells, Cultured | 3 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Subcellular Fractions/enzymology | 2 | 2.0 |
Thioredoxin Reductase (NADPH)/metabolism | 2 | 18.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Cell Division | 3 | 0.0 |
Cell Survival | 2 | 0.0 |
Apoptosis | 2 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
